N-[2-(1,6-dihydro-2H-indeno[5,4-b]furan-8-yl)ethyl]acetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: N-[2-(1,6-dihydro-2H-indeno[5,4-b]furan-8-yl)ethyl]acetamide
• 英文别名: N-[2-(2,6-dihydro-1H-cyclopenta[e][1]benzofuran-8-yl)ethyl]acetamide
• 化学式: C₁₅H₁₇NO₂
• 分子量: 243.305
• InChiKey: ZESOQCVBGGCKFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-[2-(1,6-dihydro-2H-indeno[5,4-b]furan-8-yl)ethyl]acetamide 在 四(三苯基膦)钯 、 溴 、 sodium carbonate 作用下， 以 乙醇 、 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 1.0h， 生成 N-(2-[7-(4-tert-butylphenyl)-1,6-dihydro-2H-indeno[5,4-b]-furan-8-yl]ethyl)acetamide
  参考文献：
  名称：

  1,6-Dihydro-2H-indeno[5,4-b]furan Derivatives: Design, Synthesis, and Pharmacological Characterization of a Novel Class of Highly Potent MT₂-Selective Agonists

  摘要：

  A novel series of 1,6-dihydro-2H-indeno[5,4-b]furan derivatives were designed and synthesized as MT2-selective ligands. This scaffold was identified as a potent mimic of the 5-methoxy indole core of melatonin, and introduction of a cyclohexylmethyl group at the 7-position of this scaffold afforded an MT2-selective ligand 15 (K-i = 0.012 nM) with high MT1/MT2 selectivity (799). Compound 15 was identified as a potent full agonist for the MT2 subtype and exhibited reentrainment effects to a new light/dark cycle in ICR mice at 3-30 mg/kg. This result demonstrated the involvement of the MT2 receptors in chronobiotic activity.

  DOI：

  10.1021/jm200221q
• 作为产物：
  描述：

  2-(1,2,6,7-tetrahydro-8H-indeno[5,4-b]furan-8-ylidene)acetonitrile 在 盐酸 、 氨 、 氢气 、 三乙胺 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 75.17h， 生成 N-[2-(1,6-dihydro-2H-indeno[5,4-b]furan-8-yl)ethyl]acetamide
  参考文献：
  名称：

  1,6-Dihydro-2H-indeno[5,4-b]furan Derivatives: Design, Synthesis, and Pharmacological Characterization of a Novel Class of Highly Potent MT₂-Selective Agonists

  摘要：

  A novel series of 1,6-dihydro-2H-indeno[5,4-b]furan derivatives were designed and synthesized as MT2-selective ligands. This scaffold was identified as a potent mimic of the 5-methoxy indole core of melatonin, and introduction of a cyclohexylmethyl group at the 7-position of this scaffold afforded an MT2-selective ligand 15 (K-i = 0.012 nM) with high MT1/MT2 selectivity (799). Compound 15 was identified as a potent full agonist for the MT2 subtype and exhibited reentrainment effects to a new light/dark cycle in ICR mice at 3-30 mg/kg. This result demonstrated the involvement of the MT2 receptors in chronobiotic activity.

  DOI：

  10.1021/jm200221q

文献信息

• Tricyclic compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06034239A1

  公开（公告）日：2000-03-07

  A compound of the formula: ##STR1## wherein R.sup.1 is an optionally substituted hydrocarbon, amino or heterocyclic group; R.sup.2 is H or an optionally substituted hydrocarbon group; R.sup.3 is H or an optionally substituted hydrocarbon or heterocyclic group; X is CHR.sup.4, NR.sup.4, O or S in which R.sup.4 is H or an optionally substituted hydrocarbon group; Y is C, CH or N; ring A is optionally substituted 5- to 7-membered ring; ring B is an optionally substituted benzene ring; and m is 1 to 4, or a salt thereof, a process for producing it, an intermediate for the production and a pharmaceutical composition comprising it are provided.

  该化合物的结构式为：##STR1## 其中R.sup.1是可选择取代的碳氢化合物、氨基或杂环基团；R.sup.2是H或可选择取代的碳氢基团；R.sup.3是H或可选择取代的碳氢或杂环基团；X是CHR.sup.4、NR.sup.4、O或S，其中R.sup.4是H或可选择取代的碳氢基团；Y是C、CH或N；环A是可选择取代的5-至7-成员环；环B是可选择取代的苯环；m为1至4，或其盐，提供了其制备方法、生产中间体和包含它的药物组合物。
• Bicyclic compounds and pharmaceutical composition containing tricyclic compound for treating or preventing sleep disorders
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1199304A1

  公开（公告）日：2002-04-24

  A compound having the following general fomula: wherein R1 is an optionally substituted hydrocarbon, amino or heterocyclic group; R2 is H or an optionally substituted hydrocarbon group; R3 is H or an optionally substituted hydrocarbon or heterocyclic group; X is CHR4, NR4, O or S in which R4 is H or an optionally substituted hydrocarbon group; R5 is H, a halogen atom, C1-6 alkyl group, a C1-6 alkoxy group, a hydroxy group, a nitro group, a cyano group or an amino group wherein the C1-6 alkyl group, the C1-6 alkoxy group and the amino group may be substituted by 1 to 5 substituents, Y is C or N; ring B is an optionally substituted benzene ring; m = 1 to 4 and n = 0 to 2; L represents a leaving group such as a halogen atom, an alkylsulfonyl group, an alkylsulfonlyoxy group and arylsulfonyloxy group; or a salt thereof.

  具有以下一般式的化合物： 其中R1是可选择取代的碳氢化合物、氨基或杂环基团；R2是H或可选择取代的碳氢基团；R3是H或可选择取代的碳氢基团或杂环基团；X是CHR4、NR4、O或S，其中R4是H或可选择取代的碳氢基团；R5是H、卤素原子、C1-6烷基基团、C1-6烷氧基团、羟基、硝基、氰基或氨基，其中C1-6烷基基团、C1-6烷氧基团和氨基可能被1至5个取代基取代，Y是C或N；环B是可选择取代的苯环；m = 1至4，n = 0至2；L代表离去基团，如卤素原子、烷基磺酰基团、烷基磺酰氧基团和芳基磺酰氧基团；或其盐。
• Pharmaceutical preparation containing copolyvidone
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US10098866B2

  公开（公告）日：2018-10-16

  A stabilized preparation which comprises: a unstable drug in a polyethylene glycol-containing preparation; and a coating agent comprising a copolyvidone instead of polyethylene glycol with which the drug is coated.

  一种稳定的制剂，包括：在聚乙二醇含制剂中的不稳定药物；以及一种包衣剂，其包衣剂包括一种共聚维酮，而不是用聚乙二醇包衣药物。
• [EN] TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE<br/>[FR] COMPOSES TRICYCLIQUES, LEUR PRODUCTION ET LEUR UTILISATION
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：WO1997032871A1

  公开（公告）日：1997-09-12

  (EN) A compound of formula (I) wherein R1 is an optionally substituted hydrocarbon, amino or heterocyclic group; R2 is H or an optionally substituted hydrocarbon group; R3 is H or an optionally substituted hydrocarbon or heterocyclic group; X is CHR4, NR4, O or S in which R4 is H or an optionally substituted hydrocarbon group; Y is C, CH or N; ring A is an optionally substituted 5- to 7-membered ring; ring B is an optionally substituted benzene ring; and m is 1 to 4, or a salt thereof, a process for producing it, an intermediate for the production and a pharmaceutical composition comprising it are provided.(FR) L'invention concerne un composé de la formule (I) dans laquelle R1 est un groupe hydrocarbure, amino ou hétérocyclique, éventuellement substitué; R2 est H ou un groupe hydrocarbure, éventuellement substitué; R3 est H ou un groupe hydrocarbure ou hétérocyclique, éventuellement subsitué; X est CHR4, NR4, O ou S, où R4 est H ou un groupe hydrocarbure éventuellement substitué; Y est C, CH ou N; A est un cycle à 5 - 7 éléments, éventuellement substitué; B est un cycle benzénique, éventuellement substitué; et m est compris entre 1 et 4. L'invention concerne également un sel de ce composé, un procédé pour le produire, un intermédiaire utile pour cette production et une composition pharmaceutique contenant ce composé.

  化合物的化学式(I)其中R1是一个可选的取代的碳氢化合物，氨基或杂环基团；R2是H或一个可选的取代的碳氢基团；R3是H或一个可选的取代的碳氢化合物或杂环基团；X是CHR4，NR4，O或S，其中R4是H或一个可选的取代的碳氢基团；Y是C，CH或N；环A是一个可选的取代的5-7元环；环B是一个可选的取代的苯环；m为1至4，或其盐，提供了制备它的过程，制备的中间体以及包含它的制药组合物。
• Percutaneous absorption preparation
  申请人：Suzuki Yasuyuki

  公开号：US20090264521A1

  公开（公告）日：2009-10-22

  Percutaneous absorption preparations which make it possible to absorb compounds having a melatonin receptor agonist activity via a convenient administration system, have favorable blood-drug-concentration-time profile and can exert a therapeutic effect on a disease caused by a decrease in secretion of melatonin at night.

  经皮吸收制剂可以通过方便的给药系统吸收具有褪黑素受体激动剂活性的化合物，具有良好的血药浓度时间曲线，并可以对由于夜间褪黑素分泌减少而引起的疾病产生治疗效果。